financetom
Business
financetom
/
Business
/
Rock Tech Lithium Receives 150 Million Euros in Letters of Support for Guben Converter
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rock Tech Lithium Receives 150 Million Euros in Letters of Support for Guben Converter
May 26, 2025 11:35 AM

08:04 AM EDT, 05/21/2025 (MT Newswires) -- Rock Tech Lithium ( RCKTF ) on Wednesday said it received up to 150 million euros in government-backed support through conditional, non-binding expressions of interest from export credit agencies in the U.K. and Finland.

The UK Export Finance and its Finnish counterpart, Finnvera, expressed interest in supporting the Guben Lithium Converter project. The support from the two export credit agencies is in addition to the European Investment Banks' previously announced proposed senior debt tranche of 150 million euros.

The debt financing will benefit from the Guben Lithium Converter project's European sourcing scheme, making the project eligible for credit guarantees from major European export credit agencies. Discussions are ongoing with additional export credit agencies from Europe, Australia and China to support the procurement of key equipment items from these countries, the company said.

"We welcome the strong backing from export credit agencies in supporting the Guben Converter project," said Rock Tech Chief Financial Officer Chris Wright. "Their engagement reflects confidence in our vision, the business case and the strategic importance of this facility for Europe's green energy transition."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
Nov 7, 2025
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting childrenImpetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen...
Globant to Deploy AI Agents Across LaLiga Under New Agreement
Globant to Deploy AI Agents Across LaLiga Under New Agreement
Nov 7, 2025
07:18 AM EST, 11/07/2025 (MT Newswires) -- Globant ( GLOB ) said Friday it signed a memorandum of understanding with LaLiga to roll out agentic artificial intelligence across the Italian soccer league's operations. The effort will use Globant's ( GLOB ) subscription model of AI Pods, teams of software agents to accelerate development and productivity, the company said. Through Sportian,...
Sylvamo Q3 Adjusted Earnings, Sales Fall
Sylvamo Q3 Adjusted Earnings, Sales Fall
Nov 7, 2025
07:18 AM EST, 11/07/2025 (MT Newswires) -- Sylvamo ( SLVM ) reported Q3 adjusted operating earnings Friday of $1.44 per diluted share, down from $2.44 a year earlier. Analysts' estimates were not readily available for comparison. Net sales for the quarter ended Sept. 30 were $846 million, compared with $965 million a year earlier. Three analysts surveyed by FactSet expected...
Docebo Q3 Net Income and Revenue Rises; Provides Q4 and 2025 Outlook
Docebo Q3 Net Income and Revenue Rises; Provides Q4 and 2025 Outlook
Nov 7, 2025
07:18 AM EST, 11/07/2025 (MT Newswires) -- Docebo ( DCBO ) , a learning platform provider with a foundation in artificial intelligence (AI) and innovation, on Friday reported a rise in its net income and total revenue in the third quarter, beating analysts' expectations. For the three-months ended Sept. 30, net income was US$6.1 million compared with net income of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved